Tennis Elbow

DUBLIN--( BUSINESS WIRE )--The "United States MAXIGESIC IV Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about MAXIGESIC IV for acute pain in the United States. A detailed picture of the MAXIGESIC IV for acute pain in the United States for the study period 2019 -2032 is provided in this report along with a detailed description of the MAXIGESIC IV for acute pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the MAXIGESIC IV market forecast analysis for acute pain in the US, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in acute pain. Drug Summary MAXIGESIC IV (paracetamol + ibuprofen), a novel, patented, dual mode-of-action non-opioid pain treatment, is a unique combination of paracetamol (known as acetaminophen in the US) 1,000 mg + ibuprofen 300 mg solution for infusion for use postoperatively in hospitals for patients for whom the use of oral analgesics is limited. This specific combination is designed to allow the maximum daily dose of paracetamol and ibuprofen and to allow for the effect of paracetamol on phenylephrine when combined, the level of phenylephrine crossing into the bloodstream effectively doubles. MAXIGESIC reduces fever and temporarily relieves pain associated with headaches, migraines, tension headaches, sinus pain, toothache, dental procedures, backache, sore throat, arthritis, tennis elbow, period pain, muscular pain, rheumatic pain, aches and pains associated with colds and flu. The drug is a unique patented combination of paracetamol and ibuprofen, proven to provide fast and effective relief from a wide range of pain symptoms. MAXIGESIC IV Analytical Perspective In-depth MAXIGESIC IV Market Assessment This report provides a detailed market assessment of MAXIGESIC IV for acute pain in the United States. This segment of the report provides forecasted sales data from 2023 to 2032. MAXIGESIC IV Clinical Assessment The report provides the clinical trials information of MAXIGESIC IV for acute pain covering trial interventions, trial conditions, trial status, start and completion dates. Report Highlights In the coming years, the market scenario for acute pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence MAXIGESIC IV dominance. Other emerging products for acute pain are expected to give tough market competition to MAXIGESIC IV and launch of late-stage emerging therapies in the near future will significantly impact the market. A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of MAXIGESIC IV in acute pain. Our in-depth analysis of the forecasted sales data of MAXIGESIC IV from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the MAXIGESIC IV in acute pain. Key Questions Answered What is the product type, route of administration and mechanism of action of MAXIGESIC IV? What is the clinical trial status of the study related to MAXIGESIC IV in acute pain and study completion date? What are the key collaborations, mergers and acquisitions, licensing and other activities related to the MAXIGESIC IV development? What are the key designations that have been granted to MAXIGESIC IV for acute pain? What is the forecasted market scenario of MAXIGESIC IV for acute pain? What are the forecasted sales of MAXIGESIC IV in the United States? What are the other emerging products available and how are these giving competition to MAXIGESIC IV for acute pain? Which are the late-stage emerging therapies under development for the treatment of acute pain? Key Topics Covered: 1. Report Introduction 2. MAXIGESIC IV Overview in Acute pain 2.1. Product Detail 2.2. Clinical Development 2.2.1. Clinical studies 2.2.2. Clinical trials information 2.2.3. Safety and efficacy 2.3. Regulatory Milestone 2.4. Other Developmental Activities 2.5. Product Profile 3. Competitive Landscape (Marketed Therapies) 4. Competitive Landscape (Late-stage Emerging Therapies) 5. MAXIGESIC IV Market Assessment 5.1. Market Outlook of MAXIGESIC IV in Acute pain 5.2. The United States Analysis 5.2.1. Market Size of MAXIGESIC IV in the United States for Acute pain 6. SWOT Analysis 7. Analysts' Views For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/yk65yr About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

精彩内容10月24日，九典制药公布2023年前三季度业绩，报告期内实现营收约18.93亿元，同比增长18.37%；净利润约3.1亿元，同比增长48.76%。米内网数据显示，今年以来，九典制药有6个品种获批生产并视同过评，30余个品种以新注册分类提交临床或上市申请。2023年前三季度九典制药业绩情况来源：公司公告2023年前三季度，九典制药保持营收和净利润双增长，且净利润增速高于营收增速。从单季度业绩看，Q3单季度净利润同比增长42.91%，环比Q2略有放缓，但明显高于Q1。2020-2023年同期九典制药净利润情况来源：公司公告从近年来（2020-2023年）九典制药同期业绩情况看，公司净利润呈逐年递增态势。核心产品洛索洛芬钠凝胶贴膏持续放量，虽然在医保控费的背景下可能面临一定的降价压力，但该品种具备市场先入优势，未来价格有望维持平稳。近年来中国公立医疗机构终端洛索洛芬钠凝胶贴膏销售情况来源：米内网中国公立医疗机构药品终端竞争格局九典制药以创新为中心，坚持仿创结合，丰富产品管线。米内网数据显示，今年以来，公司已有6个品种获批生产并视同过评，包括雷贝拉唑钠肠溶片、富马酸丙酚替诺福韦片、酮洛芬凝胶贴膏、枸橼酸托法替布片、非洛地平缓释片及非洛地平片。今年以来九典制药获批上市的品种来源：米内网中国申报进度（MED）数据库值得一提的是，酮洛芬凝胶贴膏为国内首仿+首家过评，主要用于骨关节炎、肩周炎、肌腱炎、腱鞘炎、腱鞘周围炎、肱骨外上髁炎（网球肘等），肌肉疼痛、外伤所致肿胀疼痛的抗炎镇痛，该品种的上市为九典制药在经皮给药领域再添“猛将”。九典制药部分在研的外用产品来源：米内网中国申报进度（MED）数据库此外，今年以来，九典制药有30余个品种以新注册分类提交临床/上市申请，包含多个外用产品，其中利多卡因凝胶贴膏、洛索洛芬钠贴剂等为外用贴剂。资料来源：米内网数据库、公司公告等注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。数据统计截至10月24日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

AAOS encourages patients to do their research, understand their options and find a reputable physician ROSEMONT, Ill., Aug. 15, 2023 /PRNewswire/ -- As orthopaedic medicine continues to advance through innovation, research and evidence-based medicine, the complexities and unknowns about newer treatments such as orthobiologics, may leave patients wondering if it is a viable treatment option for them. Orthobiologics, sometimes referred to as regenerative medicine, have shown great promise to treat conditions such as osteoarthritis; however, patients are seeking resources to understand if the treatment is right for them. To educate patients, the American Academy of Orthopaedic Surgeons (AAOS) developed an FAQ published on OrthoInfo.org, that outlines what orthobiologics are and the potential risks and benefits. Orthobiologics are a class of therapies that use biological products from human, animal or micro-organism sources such as cells, tissues or blood products like platelet-rich plasma (PRP), to leverage the body's natural physiology, and help enhance the body's healing process.i According to the FAQ, orthobiologics can be used by orthopaedic specialists to: Help relieve pain and inflammation from certain orthopaedic conditions, such as early osteoarthritis, which may help delay or negate the need for surgery Enhance the body's ability to heal from a repetitive use injury, such as a tendon strain or chronic anatomic change to the tendon known as tendinopathy In some cases, improve healing after orthopaedic surgery AAOS recognizes the potential orthobiologics could have on the future of musculoskeletal patient care, but recommends the need for additional evidence-based research and education for physicians and clear information for patients. "Many of my patients want to know more about orthobiologics and if it's worth the hype," said Jason L. Dragoo, MD, FAAOS, chair of the AAOS Devices, Biologics and Technology Committee and professor and vice chair of Academic Affairs for Colorado University Department of Orthopaedics in Denver. "While we are witnessing huge advancements in orthobiologics that have shown promise for patients suffering from knee osteoarthritis and tendinopathies, such as tennis elbow, I would encourage everyone to do their homework because it is not a viable treatment option for everyone. The regenerative therapies touted in radio ads or featured on highway billboards may not be grounded in science." Dr. Dragoo recommends patients work with a reputable physician, ideally one who does clinical research in this area and tracks their patient-outcome results. While trustworthy doctors can be found in many areas, if an orthopaedic surgeon is board certified and a fellow of the American Academy of Orthopedic Surgeons (FAAOS), it means they have met the rigorous professional and ethical standards established by AAOS. Dr. Dragoo also advises patients to: Avoid physicians who tout "stem cell therapy" or claim they can cure various musculoskeletal conditions in addition to pancreas, liver and kidney disorders, baldness and eyesight issues, as these violate the U.S. Food and Drug Administration (FDA) regulations on the use of biologics Speak to a physician about treatment options and then take the time to research those options, as well Ensure a physician conducts a full medical exam and inquiries about any systemic illnesses such as rheumatoid arthritis, lupus or cancer Determine if your insurance company will cover orthobiologic treatment, and if not, understand the out-of-pocket costs associated with the procedure "There are still a lot of unanswered questions and until we have those answers, we should proceed with caution," said Dr. Dragoo. "The AAOS is leading discussions with the FDA and other leading orthopaedic industry representatives to create evidence-based, unbiased information and guide advancements in the next five years that will help ensure more beneficial and targeted orthobiologic treatments for specific conditions." For more information about orthobiologics, visit OrthoInfo.org. About the AAOS With more than 39,000 members, the American Academy of Orthopaedic Surgeons is the world's largest medical association of musculoskeletal specialists. The AAOS is the trusted leader in advancing musculoskeletal health. It provides the highest quality, most comprehensive education to help orthopaedic surgeons and allied health professionals at every career level to best treat patients in their daily practices. The AAOS is the source for information on bone and joint conditions, treatments and related musculoskeletal healthcare issues; and it leads the healthcare discussion on advancing quality. Follow the AAOS on Facebook, Twitter, LinkedIn and Instagram. i AAOS Hosts Symposium on Orthobiologics. American Academy of Orthopaedic Surgeons. Accessed June 27, 2023. . SOURCE American Academy of Orthopaedic Surgeons